Bladder cancer is the seventh commonest cancer in the UK and the second leading cause of mortality amongst genitourinary malignancies, representing a significant health burden. In 2011, there was approximately 10,400 new diagnoses of bladder cancer and 5,100 deaths. There has been little progress in 5-year survival rates over the last two decades and hence a desperate need for new therapeutic approaches. The advances in immunotherapy and the introduction of checkpoint inhibitors marks a significant milestone for this disease. This article is protected by copyright. All rights reserved.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
BJU international. 2018 Jul 04 [Epub ahead of print]
R Dhariwal, N Pindoria, P Dasgupta, M S Khan
Guy's and St, Thomas NHS Foundation Trust.